Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02566395

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults with hematologic malignancies who lack a suitably matched related or unrelated donor. The methodology will be one that has been successfully utilized in adult patients at Thomas Jefferson University.

Status: 
Recruiting
Study Date: 
Mon, 12/01/2014 to Fri, 12/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Radiation: Radiation 1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days Other Name: Total Body Irradiation Drug: Cyclophosphamide Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days Other Name: Cytoxan Biological: Donor Lymphocyte Infusion (DLI) DLI containing 1 x 10E8/kg donor T-cells Biological: Haploidentical Stem Cell Transplantation 2-10 x 10E6/kg donor CD34+ selected cells